[{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Albendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Albendazole

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Albendazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration. Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

                          Brand Name : Albendazole-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 29, 2021

                          Lead Product(s) : Albendazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner